menu
    • menu

    Company profile for Bioheng Biotech

    NEW Drugs in Dev: 9
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents p...
    BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bioheng BiotechChina Flag
    Country
    Country
    China
    Address
    Address
    Block B1-2, 73 Tanmi Road, Pukou District, Nanjing, China
    Telephone
    Telephone
    025-85590456
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bioheng.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CAR-T therapy safe for relapsed or refractory T-cell malignancies, finds study
    CAR-T therapy safe for relapsed or refractory T-cell malignancies, finds study

    30 Sep 2022

    // Catherine Eckford EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/174730/car-t-therapy-safe-for-relapsed-or-refractory-t-cell-malignancies-finds-study/

    Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
    30 Sep 2022
    Share Share
    Bioheng Biotech Announces Publication of Impressive Results CD7-targeted CAR-T
    Bioheng Biotech Announces Publication of Impressive Results CD7-targeted CAR-T

    26 Sep 2022

    // BIOSPACE

    https://www.biospace.com/article/releases/bioheng-biotech-announces-publication-of-impressive-results-with-cd7-targeted-allogeneic-car-t-cell-therapy-for-relapsed-or-refractory-t-cell-malignancies/

    BIOSPACE
    26 Sep 2022
    Share Share
    Bioheng's CTB001 received ODD from the U.S. FDA
    Bioheng's CTB001 received ODD from the U.S. FDA

    28 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ctb001-bioheng-auto-car---t-product-received-orphan-drug-designation-odd-from-the-us-fda-301470432.html

    PRNEWSWIRE
    28 Jan 2022
    Share Share
    US FDA grants orphan drug designation to Bioheng Biotech’s CTD401 to treat T-ALL
    US FDA grants orphan drug designation to Bioheng Biotech’s CTD401 to treat T-ALL

    22 Jun 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=139435&sid=2

    PHARMABIZ
    22 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search